CIK 0001404281
- Non-accelerated filer
- Smaller reporting company
Eledon Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 949-238-8090
- Business address
- 19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA, 92612
- Former names
- Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Chief Executive Officer bought 2,000 shares at $4.48 ($8,960)
- 4 Open-market buy Chief Executive Officer bought 4,000 shares at $6.21 ($24,840)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy CHIEF FINANCIAL OFFICER bought 10,000 shares at $8.87 ($88,700)
- 4 Open-market buy Chief Executive Officer bought 3,000 shares at $8.01 ($24,030)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Conversion See Explanation of Responses acquired 1,289,628 shares (conversion)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale 10% owner sold 103,200 shares at $21.60 ($2,229,120)
- 4 Open-market buy 10% owner bought 92,040 shares at an average $25.44 ($2,341,714)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 4 of 11 · 212 filings